Concepedia

Author

Takashi Kojima

National Cancer Center Hospital EastORCID

Also Known As

Kojima Takashi, T Kojima, T. Kojima, TAKASHI KOJIMA, Takashi Kojima

358

Publications

11.4K

Citations

47

H-Index

93

Concepts

All Affiliations

National Cancer Center Hospital EastAichi Cancer CenterKeio UniversityShizuoka Cancer CenterSaitama Cancer Center
TK

About

Takashi Kojima is an author at National Cancer Center Hospital East specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

30

62

5K

2

Health Sciences

16

22

2.6K

3

Cell Biology

3

3

62

4

Public Health

2

2

361

5

Engineering

1

1

36

Takashi Kojima

×

145

Publications

10.8K

Citations

46

H-Index

YearCitations

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong‐Mu Sun, Lin Shen, Manish A. Shah,

The Lancet

2021

1.5K

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima, Manish A. Shah, Kei Muro,

Journal of Clinical Oncology

2020

1.1K

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Shota Fukuoka, Hiroki Hara, Naoki Takahashi,

Journal of Clinical Oncology

2020

887

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

Manish A. Shah, Takashi Kojima, Daniel Hochhauser,

JAMA Oncology

2018

511

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

Toshihiro Kudo, Yasuo Hamamoto, Ken Kato,

The Lancet Oncology

2017

378

Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1

Yuko Kitagawa, Ryu Ishihara, Hitoshi Ishikawa,

Esophagus

2023

345

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

Koji Kurose, Yoshihiro Ohue, Hisashi Wada,

Clinical Cancer Research

2015

249

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

Jianming Xu, Ken Kato, Eric Raymond,

The Lancet Oncology

2023

248

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

Takashi Kojima, Kei Muro, Éric François,

Journal of Clinical Oncology

2019

207

A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.

Ken Kato, Yoshinori Ito, Hiroyuki Daiko,

Journal of Clinical Oncology

2022

191

Page 1